³ÉÈË¿ìÊÖ

I refer the member to the answer to question S5W-10188 on 2 August 2017. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at:

Ìý

Ìý

The Scottish Government does not hold this information.

Ìý

Ìý

I wrote to Vertex Pharmaceuticals in March to encourage them to take forward discussions about the cost of Orkambi® with colleagues in National Health Services Scotland who are best placed to advise them on pricing approaches and a fair price that could support the securing of a positive recommendation from the Scottish Medicines Consortium for the prescribing of these products in NHSScotland. Those talks are underway.

Through those discussions we hope that the manufacturer will make their best offer on price and indicate that they will re-submit an application for Orkambi® to the SMC.

Ìý

Ìý

The Scottish Medicines Consortium is working in collaboration with patient groups, health boards, pharmaceutical companies, the Scottish Government and other stakeholders on the review of the definitions of end-of-life, orphan and ultra-orphan medicines. This work is progressing at pace.

Ìý

Ìý

Dr Brian Montgomery considered the views of a wide range of diverse stakeholders across Scotland as part of his independent review into access to new medicines and these influenced his final report and 28 recommendations. We continue to work with a diverse range of stakeholders and partners as we implement the recommendations.

I wrote to Vertex Pharmaceuticals in March to encourage them to take forward discussions about the cost of Orkambi® with colleagues in National Health Services Scotland who are best placed to advise them on pricing approaches and a fair price that could support the securing of a positive recommendation from the Scottish Medicines Consortium for the prescribing of these products in NHSScotland. Those talks are underway.

Through those discussions we hope that the manufacturer will make their best offer on price and indicate that they will re-submit an application for Orkambi® to the SMC.

Ìý

Ìý

The New Medicines Fund (NMF) provides financial support to NHS Boards for End of Life, Orphan and Ultra Orphan medicines which can be accessed by clinicians in a number of ways such as Individual Patient Treatment Requests, Peer Approved Clinical System requests or medicines accepted by the Scottish Medicines Consortium.

The Scottish Government is committed to continuing to invest in the NMF on the basis of the operation of the Pharmaceutical Price Regulation Scheme and these receipts will be directed into the New Medicines Fund in future years, as is currently case.

Ìý

Ìý

I refer the member to the answer to question S5W-10195 on 28 July 2017. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at:

Ìý

Ìý

I refer the member to the answer to question S5W-10195 on 28 July 2017. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at:

Ìý

Ìý

Dr Montgomery’s independent review on access to new medicines recognised that the Scottish Government has made significant reforms and investment to improve access to newly licensed medicines in recent years.

I announced in December 2016 that we will be taking forward the recommendations from the review. We are working at pace, in collaboration with stakeholders, including the Scottish Medicines Consortium, NHS Scotland, and the pharmaceutical industry to implement the recommendations as quickly as possible.

Ìý

Ìý

I refer the member to the answer to question S5W-06745 on 24 February 2017. All answers to written parliamentary questions are available on the Parliament's website, the search facility for which can be found at

Ìý

Ìý